Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 CY2025, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback